Brief: CASI Pharmaceuticals Receives Notice Of Termination Of Marqibo License Agreement From Acrotech Related To Withdrawal Of Product Marqibo From US Market
02/05/2022 21:48
May 2 (Reuters) - CASI Pharmaceuticals Inc CASI.O :
* CASI PHARMACEUTICALS- RECEIVED NOTICE OF TERMINATION OF
MARQIBO
LICENSE AGREEMENT FROM ACROTECH RELATED TO WITHDRAWAL OF
PRODUCT MARQIBO FROM US MARKET
* CASI PHARMACEUTICALS INC- MUTUALLY AGREED TO TERMINATE
ORIGINAL
MARQIBO LICENSE AGREEMENT DATED SEPT 17, 2014 BETWEEN TALON
THERAPEUTICS AND THE CO
* CASI PHARMACEUTICALS INC- ACROTECH ASSUMED THE MARQIBO
LICENSE
AGREEMENT FROM TALON
Source: [ID: https://bit.ly/377do1R]
Further company coverage: CASI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary